Family Medicine Pharmacy, LLC v. Impax Laboratories, Inc.

CourtDistrict Court, S.D. Alabama
DecidedSeptember 29, 2017
Docket1:17-cv-00053
StatusUnknown

This text of Family Medicine Pharmacy, LLC v. Impax Laboratories, Inc. (Family Medicine Pharmacy, LLC v. Impax Laboratories, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. Alabama primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Family Medicine Pharmacy, LLC v. Impax Laboratories, Inc., (S.D. Ala. 2017).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF ALABAMA SOUTHERN DIVISION

FAMILY MEDICINE PHARMACY, LLC, ) ) Plaintiff, ) ) v. ) CIVIL ACTION 17-0053-WS-MU ) IMPAX LABORATORIES, INC., ) ) Defendant. )

ORDER This matter comes before the Court on Plaintiff’s Unopposed Motion for Preliminary Approval of Class Action Settlement and Certification of Settlement Class (doc. 48). The Motion has been briefed and is now ripe for disposition. I. Background. Plaintiff, Family Medicine Pharmacy, LLC, brought this putative class action against defendant, Impax Laboratories, Inc., alleging violations of the Telephone Consumer Protection Act of 1991, 47 U.S.C. § 227, as amended by the Junk Fax Prevention Act of 2005 (the “TCPA”). In particular, Family Medicine maintained that it had received an unsolicited “junk fax” advertising the commercial availability and qualities of Impax’s epinephrine auto-injector device on December 21, 2016, in violation of the TCPA’s prohibition on transmission of unsolicited advertisements by facsimile machine, computer, or other device. See 47 U.S.C. § 227(b)(1)(C). Plaintiff further alleged that this fax transmission violated the TCPA by failing to provide the recipient with a cost-free mechanism to opt out of receiving such transmissions in the future. See 47 U.S.C. § 227(b)(2)(D). By its terms, the TCPA provides for a private right of action, and authorizes recovery of the greater of actual damages or statutory damages of $500, or up to treble that amount for willful or knowing violations. See 47 U.S.C. § 227(b)(3). This action has been litigated vigorously, with substantial motion practice, amended pleadings, and both formal and informal sharing of discovery materials. A critical legal issue concerns Impax’s assertion that the subject fax transmissions were outside the scope of the TCPA because they were not commercial advertisements, but were rather informational in nature. The parties negotiated extensively for several months, with such negotiations culminating in a mediation session on July 18, 2017 that yielded settlement of this dispute in its entirety. The agreement is memorialized in a 41-page Settlement Agreement and Release executed by the parties on August 23, 2017. (See doc. 49, Exh. 1.) In summary, the key settlement terms include the following: (i) Impax will pay the sum of $4,815,700 in cash into a settlement fund, to be distributed on a pro rata basis to class members making claims, such distributions not to exceed $500 per compensable fax transmission; (ii) Impax will pay an additional sum of $75,000 toward the costs of notice and claims administration; (iii) plaintiff’s attorney’s fees and litigation expenses of up to one-third of the settlement fund less administration costs will be paid from the settlement fund, subject to court approval; and (iv) plaintiff, Family Medicine Pharmacy, LLC, will request a class representative incentive award of up to $20,000, to be paid from the corpus of the settlement fund. Family Medicine, with the acquiescence of Impax, now petitions the Court for preliminary approval of the settlement agreement and conditional certification of a settlement class pursuant to Rule 23 of the Federal Rules of Civil Procedure. II. Motion for Conditional Certification of Settlement Class. Plaintiff seeks conditional certification of a settlement class (the “Settlement Class”) whose parameters would be defined as follows: “All individuals and/or entities who[] or which received one or more unsolicited advertisements via facsimile from Defendant between December 1, 2013 and the date of entry of the Preliminary Approval Order.” (Doc. 49, Exh. 1, § 8.3.) Through formal and informal discovery, including fax records supplied by the third party retained by Impax to send the subject facsimiles, the parties have identified approximately 48,157 individuals and entities that fall within the boundaries of this Settlement Class definition. “A class action may be maintained only when it satisfies all the requirements of Fed.R.Civ.P. 23(a) and at least one of the alternative requirements of Rule 23(b).” Rutstein v. Avis Rent-A-Car Systems, Inc., 211 F.3d 1228, 1233 (11th Cir. 2000) (citation omitted). Here, Family Medicine seeks certification of a settlement class under Rules 23(a) and 23(b)(3). Before reaching the Rule 23 criteria, the Court must determine whether the proposed class is “adequately defined and clearly ascertainable.” Little v. T-Mobile USA, Inc., 691 F.3d 1302, 1304 (11th Cir. 2012) (citations omitted).1 “In order to establish ascertainability, the plaintiff must propose an administratively feasible method by which class members can be identified.” Karhu v. Vital Pharmaceuticals, Inc., 621 Fed.Appx. 945, 947 (11th Cir. June 9, 2015). “Administrative feasibility means that identifying class members is a manageable process that does not require much, if any, individual inquiry.” Bussey v. Macon County Greyhound Park, Inc., 562 Fed.Appx. 782, 787 (11th Cir. Apr. 2, 2014) (citations and internal quotation marks omitted). Family Medicine has met this requirement by proposing a manageable, logistically straightforward means of identifying class members. In particular, Family Medicine explains that Impax used a third party to send facsimiles; that said third party has supplied fax records to Impax showing the names and fax numbers of the fax recipients; that Impax maintained certain additional records; and that using these records, defendant has compiled a list (the “Notice List”) containing the name of each recipient, along with that recipient’s city, state, zip code, fax number, and frequency and dates of faxes transmitted. As such, the Notice List provides a readily available, administratively feasible means of identifying and locating all class members via a manageable process that will require little, if any, individual inquiry. The ascertainability prerequisite for class certification is thus satisfied here.

1 Actually, the very first question to examine in the class certification context is whether “at least one named class representative has Article III standing to raise each class subclaim.” Murray v. Auslander, 244 F.3d 807, 810 (11th Cir. 2001) (citations omitted). It is a “well-settled rule” that “any analysis of class certification must begin with the issue of standing.” Id. (citation omitted). “To establish Article III standing, an injury must be concrete, particularized, and actual or imminent; fairly traceable to the challenged action; and redressable by a favorable ruling.” Clapper v. Amnesty Int’l USA, 133 S.Ct. 1138, 1147, 185 L.Ed.2d 264 (2013) (citations and internal quotation marks omitted). Here, it cannot seriously be questioned that Family Medicine, as the recipient of an unsolicited fax from Impax, possesses the requisite Article III standing to raise claims under the TCPA. See Palm Beach Golf Center-Boca, Inc. v. John G. Sarris, D.D.S., P.A., 781 F.3d 1245, 1251 (11th Cir.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Valley Drug Co. v. Geneva Pharmaceuticals, Inc.
350 F.3d 1181 (Eleventh Circuit, 2003)
Adams v. Southern Farm Bureau Life Insurance
493 F.3d 1276 (Eleventh Circuit, 2007)
Vega v. T-MOBILE USA, INC.
564 F.3d 1256 (Eleventh Circuit, 2009)
Williams v. Mohawk Industries, Inc.
568 F.3d 1350 (Eleventh Circuit, 2009)
In Re Nissan Motor Corporation Antitrust Litigation
552 F.2d 1088 (Fifth Circuit, 1977)
Zuzanna Juris v. Inamed Corporation
685 F.3d 1294 (Eleventh Circuit, 2012)
Melissa K. Little v. T-Mobile USA, Inc.
691 F.3d 1302 (Eleventh Circuit, 2012)
Clapper v. Amnesty International USA
133 S. Ct. 1138 (Supreme Court, 2013)
Figueroa v. Sharper Image Corp.
517 F. Supp. 2d 1292 (S.D. Florida, 2007)
Bussey v. MacOn County Greyhound Park, Inc.
562 F. App'x 782 (Eleventh Circuit, 2014)
Adam Karhu v. Vital Pharmaceuticals, Inc.
621 F. App'x 945 (Eleventh Circuit, 2015)
Geri Siano Carriuolo v. General Motors Company
823 F.3d 977 (Eleventh Circuit, 2016)
Kevin Calderone v. Michael Scott
838 F.3d 1101 (Eleventh Circuit, 2016)
Tornes v. Bank of America, N.A.
275 F.R.D. 654 (S.D. Florida, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
Family Medicine Pharmacy, LLC v. Impax Laboratories, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/family-medicine-pharmacy-llc-v-impax-laboratories-inc-alsd-2017.